In clinical trials, cerebrolysin's reported adverse events have generally been mild: agitation, dizziness, feeling hot or flushed, and injection-site reactions. Cochrane reviews in stroke and vascular dementia found no significant overall difference in adverse-event rates versus placebo.[1][2]
Reviewed for accuracy · Last reviewed July 8, 2026The balanced reading is that short-term tolerability looks acceptable, but the safety data come largely from trials with methodological limitations. Notably, the Cochrane acute ischaemic stroke review flagged a possible increase in non-fatal serious adverse events at higher doses (30 mL for 10 days), so tolerability should not be read as evidence of benefit.
Because cerebrolysin is administered by healthcare professionals, any reaction during or after an infusion should be raised with the treating clinician rather than managed independently.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.